Zendal Group
Press
Careers

You are on Vetia’s International website.

Go to Vetia Spain

AUCHSKY Vacuna para la inmunización activa de porcino para prevenir la enfermedad de Aujeszky

The packaging image may vary depending on the country in which it is marketed.

Logotipo CZ Vaccines
Manufacturer
CZ Vaccines, S.A.U
Medicinal product subject to veterinary prescription

AUSCHKY

Vaccine for the active immunisation of pigs against Aujeszky’s disease. Lyophilised and solvent for injectable suspension.
REQUEST MORE INFO
Target species
Pigs icon
Pigs
Composition
Each vaccine dose (2 ml) contains:

Active substance:
Live attenuated Aujeszky’s disease virus,
Bartha K-61 strain, gE- ≥ 105,5 DICC50*

* DICC50: infectious dose in cell culture

Indications
For the active immunisation of pigs against Aujeszky’s disease. This vaccine features a gE- genetic marker, facilitating its integration into Aujeszky’s disease eradication plans by allowing differentiation between vaccine-induced antibodies and those from natural infection.
Route of administration
Intramuscular.
Dosage
Dose: 2 ml
Vaccination schedule:
  • Primary vaccination:
    • 1 dose: 10–12 weeks of age.
    • 1 dose: 3–4 weeks after the first.

  • Revaccination:
    • 1 dose: From 6 months of age.
    • 1 dose: Every 4 months.
Withdrawal period
Zero days.
AUCHSKY Vacuna para la inmunización activa de porcino para prevenir la enfermedad de Aujeszky

La imagen puede variar dependiendo del país en el que se comercialice.

Laboratorio fabricante
CZ Vaccines S.A.U.
Medicamento sujeto a prescripción veterinaria

AUSCHKY

Vaccine for the active immunisation of pigs against Aujeszky’s disease. Lyophilised and solvent for injectable suspension.
SOLICITE INFORMACIÓN
PREVENTING WITH EXPERTS
Composición
Each vaccine dose (2 ml) contains:

Active substance:
Live attenuated Aujeszky’s disease virus,
Bartha K-61 strain, gE- ≥ 105,5 DICC50*

* DICC50: infectious dose in cell culture

Indicaciones
For the active immunisation of pigs against Aujeszky’s disease. This vaccine features a gE- genetic marker, facilitating its integration into Aujeszky’s disease eradication plans by allowing differentiation between vaccine-induced antibodies and those from natural infection.
Vía de administración
Intramuscular.
Posología
Dose: 2 ml
Pauta de vacunación
  • Primary vaccination:
    • 1 dose: 10–12 weeks of age.
    • 1 dose: 3–4 weeks after the first.

  • Revaccination:
    • 1 dose: From 6 months of age.
    • 1 dose: Every 4 months.
Tiempo de espera
Zero days.
Scroll to Top